Home Others Drug-Linker Conjugates for ADC inhibitor Vipivotide tetraxetan (PSMA-617) For research use only.

Vipivotide tetraxetan (PSMA-617)

Vipivotide tetraxetan (PSMA-617) is a chemically modified PSMA(prostate-specific membrane antigen) inhibitor with a Ki of 0.37 nM.

Vipivotide tetraxetan (PSMA-617) Chemical Structure

Vipivotide tetraxetan (PSMA-617) Chemical Structure

CAS: 1702967-37-0

Selleck's Vipivotide tetraxetan (PSMA-617) has been cited by 1 publication

Purity & Quality Control

Batch: S867001 Water] 100 mg/mL] false] ] ] false] ] ] false Purity: 99.73%
99.73

Vipivotide tetraxetan (PSMA-617) Related Products

Choose Selective Drug-Linker Conjugates for ADC Inhibitors

Biological Activity

Description Vipivotide tetraxetan (PSMA-617) is a chemically modified PSMA(prostate-specific membrane antigen) inhibitor with a Ki of 0.37 nM.
Targets
PSMA [1]
(Cell-free assay)
0.37 nM(Ki)
In vitro
In vitro

PSMA-617 demonstrates high radiolytic stability for at least 72 h. A high inhibition potency (equilibrium dissociation constant Ki = 2.34 ± 2.94 nM on LNCaP; Ki = 0.37 ± 0.21 nM enzymatically determined) and highly efficient internalization into LNCaP cells are demonstrated.[1]
Cell Research Cell lines PSMA-positive LNCaP cell line
Concentrations 0–5000 nM
Incubation Time 1 h
Method

The cell-based assay is performed using 105 LNCaP cells/well. The radioligand (Glu-urea-Lys-(Ahx))2-[68Ga]Ga(HBED-CC)(19) is added as 0.75 nM solution to 12 different concentrations of non-labeled, natGa- or natLu-labeled PSMA-617 (from 0 to 5000 nM). After 1 hour incubation at 37 ℃, the cells are washed with ice-cold PBS and the cell-bound radioactivity is measured in a gamma counter.
In Vivo
In vivo

The small-animal PET measurements show high tumor-to-background contrasts as early as 1 h after injection. In vivo distribution reveals specific uptake in LNCaP tumors and in the kidneys 1 h after injection. With regard to therapeutic use, PSMA-617 exhibits a rapid clearance from the kidneys from 113.3 ± 24.4 at 1 h to 2.13 ± 1.36 percentage injected dose per gram at 24 h. The favorable pharmacokinetics of the molecule leads to tumor-to-background ratios of 1,058 (tumor to blood) and 529 (tumor to muscle), respectively,24 h after injection.[1]
Animal Research Animal Models 8-wk-old BALB/c nu/nu mice which are subcutaneously inoculated into the right trunk with 5 × 106 LNCaP cells in 50% Matrigel.
Dosages ~30 MBq, 0.5 nM for small-animal PET imaging; ~1 MBq, 0.06 nM for organ distribution.
Administration IV
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05766371 Recruiting
Castrate Resistant Prostate Cancer|Metastatic Castration-resistant Prostate Cancer|Prostate Cancer|Prostate Carcinoma
University of California San Francisco|Merck Sharp & Dohme LLC|Prostate Cancer Foundation
 December 15 2023 Phase 2
NCT06004661 Not yet recruiting
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals|Novartis
 December 29 2023 Phase 2
NCT05228106 Recruiting
Solid Cancers
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
 January 21 2022 --
NCT05219500 Recruiting
Metastatic Castration Resistant Prostate Cancer
Excel Diagnostics and Nuclear Oncology Center
 December 16 2021 Phase 2

Chemical Information & Solubility

Molecular Weight 1042.14 Formula

C49H71N9O16
CAS No. 1702967-37-0 SDF --
Smiles C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

Water : 100 mg/mL


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Vipivotide tetraxetan (PSMA-617) | Vipivotide tetraxetan (PSMA-617) supplier | purchase Vipivotide tetraxetan (PSMA-617) | Vipivotide tetraxetan (PSMA-617) cost | Vipivotide tetraxetan (PSMA-617) manufacturer | order Vipivotide tetraxetan (PSMA-617) | Vipivotide tetraxetan (PSMA-617) distributor